This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

GLP-1: Acute Effects on Kidney Function in Healthy Men

This study has been completed.
Novo Nordisk A/S
Information provided by (Responsible Party):
Jeppe Skov, University of Aarhus Identifier:
First received: April 8, 2011
Last updated: December 14, 2011
Last verified: December 2011
The purpose of this study is to investigate how Glucagon-Like Peptide 1 (GLP-1) affects kidney function in healthy young men. The hypothesis is that GLP-1 induces a positive effect on kidney hemodynamics.

Condition Intervention
Kidney Functional Biological: Human GLP-1 (7-36) amide Biological: Isotone NaCl

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: GLP-1: Acute Effects on Kidney Function in Healthy Men

Further study details as provided by Jeppe Skov, University of Aarhus:

Primary Outcome Measures:
  • Glomerular Filtration Rate [ Time Frame: Every 20 minutes for 6 hours ]

Enrollment: 12
Study Start Date: May 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: GLP-1 Biological: Human GLP-1 (7-36) amide
2 hour IV infusion, 1,5pmol/min/kg.
Placebo Comparator: Placebo Biological: Isotone NaCl
2 hours IV infusion.


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy young men

Exclusion Criteria:

  • Any chronic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01333163

Klinisk Institut, Afd. MEA, Aarhus Sygehus, NBG
Aarhus C, Denmark, 8000
Sponsors and Collaborators
Jeppe Skov
Novo Nordisk A/S
Principal Investigator: Jeppe Skov, MD University of Aarhus
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jeppe Skov, MD, University of Aarhus Identifier: NCT01333163     History of Changes
Other Study ID Numbers: VEKRM 29414
Study First Received: April 8, 2011
Last Updated: December 14, 2011

Additional relevant MeSH terms:
Glucagon-Like Peptide 1
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Gastrointestinal Agents processed this record on September 19, 2017